Abstracts tagged "immunosuppressants"

Abstract Number: 2273 • 2014 ACR/ARHP Annual Meeting
Does a Standardized Multidisciplinary Approach Improve Outcomes for Children with NMDA Receptor Antibody Encephalitis? : A Preliminary Assessment of a Single Center Experience
Mered Parnes¹, Amber Stocco², Trung Nguyen³, Jun Teruya⁴, Jeanine Graf³ and Eyal Muscal⁵, ¹Child Neurology, Baylor College of Medicine, Houston, TX, ²Integris Pediatric Neurology, Oklahoma City, OK, ³Pediatrics-critical care, Baylor College of Medicine, Houston, TX, ⁴Pathology, Baylor College of Medicine, Houston, TX, ⁵Immunology, Allergy, and Rheumatology, Baylor College of Medicine, Houston, TX
Background/Purpose: NMDA receptor antibody encephalitis (NMDAR) is a potentially devastating isolated autoimmune condition affecting children and young adults that was mostly unrecognized prior to 2007.…
Abstract Number: 1765 • 2014 ACR/ARHP Annual Meeting
Comparison of Clinical Characteristics of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis By the Serotype Specificity to Myeloperoxidase and Proteinase-3
Takamasa Murosaki, Takeo Sato, Yoichiro Akiyama, Katsuya Nagatani and Seiji Minota, Division of Rheumatology and Clinical Immunology, Jichi Medical University, Tochigi, Japan
Background/Purpose: To correlate the clinical characteristics of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) with myeloperoxidase (MPO)-ANCA and proteinase-3 (PR3)-ANCA, and to detect clinical characteristics of…
Abstract Number: 1671 • 2014 ACR/ARHP Annual Meeting
Renal Relapses Are Common in Lupus Nephritis
Angela Pakozdi¹, Ravindra Rajakariar², Michael Sheaff³ and Dev Pyne¹, ¹Rheumatology, Barts Health NHS Trust, London, United Kingdom, ²Renal Medicine, Barts Health NHS Trust, London, United Kingdom, ³Histopathology, Barts Health NHS Trust, London, United Kingdom
Background/Purpose Renal relapses are part of the natural history of lupus nephritis (LN) and represent a significant challenge not only because they are associated with…
Abstract Number: 1663 • 2014 ACR/ARHP Annual Meeting
Influence of Ethnicity on Efficacy of Current Immunosuppressive Protocols in Proliferative Lupus Nephritis
Angela Pakozdi¹, Ravindra Rajakariar², Michael Sheaff³ and Dev Pyne¹, ¹Rheumatology, Barts Health NHS Trust, London, United Kingdom, ²Renal Medicine, Barts Health NHS Trust, London, United Kingdom, ³Histopathology, Barts Health NHS Trust, London, United Kingdom
Background/Purpose Lupus nephritis (LN) is a major complication of systemic lupus erythematous (SLE) and prevalence is estimated to be 50-60%. Recently, variable responses to induction…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].